DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Daliresp (Roflumilast) - Summary



The active ingredient in DALIRESP tablets is roflumilast. Roflumilast and its active metabolite (roflumilast N-oxide) are selective phosphodiesterase 4 (PDE4) inhibitors.

DALIRESP® is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

Limitations of Use

DALIRESP is not a bronchodilator and is not indicated for the relief of acute bronchospasm.

See all Daliresp indications & dosage >>


Published Studies Related to Daliresp (Roflumilast)

Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial. [2008]
of roflumilast in a human model of segmental bronchial endotoxin challenge... CONCLUSIONS: Roflumilast attenuated the endotoxin-induced influx of neutrophils

Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. [2007]
exacerbation frequency over 1 year in patients with stable COPD... CONCLUSIONS: In severe, stable COPD, PDE4 inhibition with roflumilast produced a

Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge. [2007]
asthmatic response to allergen challenge... CONCLUSIONS: Roflumilast attenuated allergen-induced AHR in patients with mild

Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis. [2014]
AIM: To assess the efficacy and safety of roflumilast in COPD patients... CONCLUSIONS: Roflumilast significantly reduces the mean exacerbation rate in COPD

High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast. [2011]
to determine the absolute bioavailability of ROF in humans... CONCLUSION: ROF is rapidly absorbed after PO administration and exhibits high

more studies >>

Reports of Suspected Daliresp (Roflumilast) Side Effects

Diarrhoea (46)Nausea (42)Decreased Appetite (37)Insomnia (37)Weight Decreased (33)Headache (27)Dyspnoea (27)Dizziness (25)Tremor (23)Anxiety (22)more >>

Page last updated: 2014-11-30

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015